Page 150 - 72_01

M. TERESA GÓMEZ-CASARES Y COLS. AN. R. ACAD. NAC. FARM.

(3) HANDA, H.; HEGDE, U. P.; KOTELNIKOV, V. M.; MUNDLE, S. D.; DONG, L. M.;
BURKE, P.; ROSE, S.; GASKIN, F.; RAZA, A. and PREISLER, H. D. (1997): Bcl-2 and
(4) c-myc expression, cell cycle kinetics and apoptosis during the progression of
(5) chronic myelogenous leukemia from diagnosis to blastic phase. Leuk. Res.
(6) 21: 479-89.
(7) DEININGER, M. W.; GOLDMAN, J. M. and MELO, J. V. (2000): The molecular
biology of chronic myeloid leukemia. Blood 96: 3343-56.
(8) DAN, S.; NAITO, M. and TSURUO, T. (1998): Selective induction of apoptosis in
(9) Philadelphia chromosome-positive chronic myelogenous leukemia cells by
(10) an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Cell Death Differ. 5:
710-5.
FANG, G.; KIM, C. N.; PERKINS, C. L.; RAMADEVI, N.; WINTON, E.; WITTMANN, S.
and BHALLA, K. N. (2000): CGP57148B (STI-571) induces differentiation and
apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis
due to antileukemic drugs. Blood 96: 2246-53.
SILVER, R. T.; WOOLF, S. H.; HEHLMANN, R.; APPELBAUM, F. R.; ANDERSON, J.;
BENNETT, C.; GOLDMAN, J. M.; GUILHOT, F.; KANTARJIAN, H. M.; LICHTIN, A. E.;
TALPAZ, M. and TURA, S. (1999): An evidence-based analysis of the effect
of busulfan, hydroxyurea, interferon, and allogeneic bone marrow
transplantation in treating the chronic phase of chronic myeloid leukemia:
developed for the American Society of Hematology. Blood 94: 1517-36.
DRUKER, B. J. (2002): STI571 (Gleevec) as a paradigm for cancer therapy.
Trends Mol. Med. 8: S14-8.
LERGA, A.; RICHARD, C.; DELGADO, M. D.; CANELLES, M.; FRADE, P.; CUADRADO, M.
A. and LEON, J. (1999): Apoptosis and mitotic arrest are two independent
effects of the protein phosphatases inhibitor okadaic acid in K562 leukemia
cells. Biochem. Biophys. Res. Commun. 260: 256-64.
HOLTZ, M. S.; SLOVAK, M. L.; ZHANG, F.; SAWYERS, C. L.; FORMAN, S. J. and
BHATIA, R. (2002): Imatinib mesylate (STI571) inhibits growth of primitive
malignant progenitors in chronic myelogenous leukemia through reversal of
abnormally increased proliferation. Blood 99: 3792-800.

36